A research article publishe on 10 April 2020 found that including Benlysta (Belumimab) in the lupus treatment regimen early on in the disease course may promote better outcomes.
Benlysta Found to Effectively Change B-cell Levels
In a new study, researchers looked at whether treatments targeting B-cell activating factor (BAFF) have an impact on human B-cells, as previous studies have suggested. B-cells are responsible for creating antibodies, including autoantibodies, and are thought to play a role in the development and progression of autoimmune diseases.
